✦ LIBER ✦

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease

✍ Scribed by Gord Blackhouse; Nazila Assasi; Feng Xie; John Marshall; E. Jan Irvine; Kathryn Gaebel; Kaitryn Campbell; Rob Hopkins; Daria O’Reilly; Jean-Eric Tarride; Ron Goeree

Book ID: 119223379
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 608 KB
Volume: 6
Category: Article
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2011.07.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PGI26 CANADIAN COST-UTILITY ANALYSIS OF

PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE

✍ G Blackhouse; F Xie; N Assasi; K Gaebel; J Marshall; EJ Irvine; D Robertson; R G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

P082 - Fabrication and assessment of mic

P082 - Fabrication and assessment of microspheres loaded with anti-TNF-α as a prospective novel treatment for Crohn's disease fistulae

✍ R. Day; K. Foong; I. Goubareva; A. Forbes 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 53 KB

American Gastroenterological Association

American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

✍ Terdiman, Jonathan P.; Gruss, Claudia B.; Heidelbaugh, Joel J.; Sultan, Shahnaz; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 830 KB

American Gastroenterological Association

American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

✍ Dassopoulos, Themistocles; Sultan, Shahnaz; Falck–Ytter, Yngve T.; Inadomi, John 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Su1212 Incidence of Surgery and Associat

Su1212 Incidence of Surgery and Associated Costs At 1 and 2 Years in Patients Newly Initiated to a Subcutaneous Anti-TNF for the Treatment of Crohn's Disease

✍ Kane, Sunanda V.; Jenkins, Sunni; Jaganathan, Srihari; Schwartz, David A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 370 KB

Health-economic analysis: cost-effective

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults

✍ J. LINDSAY; Y. S. PUNEKAR; J. MORRIS; G. CHUNG-FAYE 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB